Message from the Chair

Wolfgang Dillmann, MD Announcement May 14, 2014, from Wolfgang H. Dillmann, MD, Helen M. Ranney Distinguished Professor and Chair of the Department of Medicine 

Dr. Catriona JamiesonPlease join me in officially welcoming Catriona Jamieson, MD, PhD, as the inaugural chief of the new Division of Regenerative Medicine. The Department of Medicine is delighted to announce the inception of the Division of Regenerative Medicine and we enthusiastically support Dr. Jamieson’s talent and vision for this innovative endeavor. 

Dr. Jamieson joined the UC San Diego faculty in 2005 and is an associate professor of Medicine in the Division of Hematology-Oncology. She has proven her leadership skills, expertise and effectiveness in her current positions as director of the Stem Cell Research Program at Moores Cancer Center, co-leader of the Hematologic Malignancies Program, hematology team leader, co-director of the UC San Diego Stem Cell Training Grant, coordinating course director of the Interdisciplinary Stem Cell course, and a co-director of the new Sanford Stem Cell Clinical Center. 

Dr. Jamieson received her medical and doctorate degrees from the University of British Columbia. She completed her residency and clinical fellowships in bone marrow transplantation and hematology, as well as her postdoctoral research fellowship in the laboratory of Professor Irving Weissman at Stanford. 

As a physician-scientist, Dr. Jamieson specializes in leukemia and myeloproliferative neoplasms, which are a family of uncommon, but not rare, degenerative disorders in which the body overproduces blood cells. These disorders can cause blood clotting which can lead to heart attack, stroke, and other life-threatening complications including transformation to acute leukemia. 

Dr. Jamieson’s research focuses on the mutant stem cells and progenitor cells in myeloproliferative neoplasms, which can give rise to cancer stem cells. Her stem-cell research studies have taken a substantial leap from identifying a promising treatment in the laboratory to completing the first clinical trial targeting cancer stem cells in humans. Her discoveries in myeloproliferative neoplasms are now being brought together with a drug development track of a regional pharmaceutical company. 

Please join me in giving your enthusiastic support to Dr. Jamieson in her new leadership role as the inaugural chief of the Division of Regenerative Medicine here at UC San Diego. This is a unique and exciting opportunity to make UC San Diego a key hub for the rapid translation of stem cell discoveries to the clinic.